Mezlocillin in gonorrhoea: a pilot study

Fowler, W.; Khan, M. H.

doi:10.1185/03007997909109015

Cited by 4 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Microbiology, Pharmacology, and Clinical Use of Mezlocillin Sodium

McCloskey

LeFrock²,

Smith³

et al. 1982

Pharmacotherapy

View full text Add to dashboard Cite

The acylureido penicillin mezlocillin is active against gram-positive, gram-negative, and anaerobic bacteria. It easily penetrates the outer membrane of gram-negative bacteria, and it has a strong affinity for penicillin binding protein 3. Its stability to beta-lactamases is weak. Mezlocillin is synergistic when given in combination with aminoglycoside antibiotics. In pharmacokinetic studies mezlocillin conforms to a two compartment open model; its pharmacokinetic properties are dose-dependent. The half-life of the drug is about 1 hour after intravenous injection and 1.5 hours after intramuscular injection. Protein binding ranges from 16 to 42%, and 55% of a dose is excreted in the urine. Biliary excretion ranges from 0.5 to 25%. Clinical trial cure rates were as follows: bacteremia (78%), respiratory tract (62%), urinary tract (81%), gynecological (86%), bone and joint (55%), intraabdominal (67%) and skin and soft tissue (59%). The frequency of adverse reactions was 7.7%. Interstitial nephritis, CNS toxicity, and bleeding have not been reported.

show abstract

Microbiology, Pharmacology, and Clinical Use of Mezlocillin Sodium

McCloskey

LeFrock²,

Smith³

et al. 1982

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Therapeutic Application of β-Lactam Antibiotics

Uri¹,

Actor²

1983

Antibiotics

View full text Add to dashboard Cite

Mezlocillin in the treatment of gonorrhea

Kataniwa

Mizuma

1982

Infection

View full text Add to dashboard Cite

Mezlocillin (2 g) was administered by a single intravenous injection to 32 male patients with gonorrheal urethritis and to five female patients with gonorrheal cervicitis, none of whom had received any pre-treatment or had had any complications. The results of the treatment were "good" in 32 cases (86.5%), "fair" in three (8.1%) and "poor" in two patients (5.4%). One of the two "poor" cases showed no sensitivity to any penicillin derivative. Nausea during injection was observed twice, but the patients recovered immediately after the injection.

show abstract

Mezlocillin in gonorrhoea: a pilot study

Cited by 4 publications

References 3 publications

Microbiology, Pharmacology, and Clinical Use of Mezlocillin Sodium

Microbiology, Pharmacology, and Clinical Use of Mezlocillin Sodium

Therapeutic Application of β-Lactam Antibiotics

Mezlocillin in the treatment of gonorrhea

Contact Info

Product

Resources

About